- Home
- ESSA vs VTYX Comparison
ESSA vs VTYX Comparison
Compare ESSA & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESSA
- VTYX
- Stock Information
- Founded
- ESSA 1916
- VTYX 2018
- Country
- ESSA United States
- VTYX United States
- Employees
- ESSA N/A
- VTYX N/A
- Industry
- ESSA Banks
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- ESSA Finance
- VTYX Health Care
- Exchange
- ESSA Nasdaq
- VTYX Nasdaq
- Market Cap
- ESSA 184.4M
- VTYX 154.9M
- IPO Year
- ESSA N/A
- VTYX 2021
- Fundamental
- Price
- ESSA $18.47
- VTYX $2.26
- Analyst Decision
- ESSA
- VTYX Buy
- Analyst Count
- ESSA 0
- VTYX 4
- Target Price
- ESSA N/A
- VTYX $11.33
- AVG Volume (30 Days)
- ESSA 18.6K
- VTYX 2.3M
- Earning Date
- ESSA 07-23-2025
- VTYX 08-07-2025
- Dividend Yield
- ESSA 3.25%
- VTYX N/A
- EPS Growth
- ESSA N/A
- VTYX N/A
- EPS
- ESSA 1.55
- VTYX N/A
- Revenue
- ESSA $66,345,000.00
- VTYX N/A
- Revenue This Year
- ESSA $9.38
- VTYX N/A
- Revenue Next Year
- ESSA N/A
- VTYX N/A
- P/E Ratio
- ESSA $11.93
- VTYX N/A
- Revenue Growth
- ESSA N/A
- VTYX N/A
- 52 Week Low
- ESSA $15.82
- VTYX $0.78
- 52 Week High
- ESSA $22.22
- VTYX $3.39
- Technical
- Relative Strength Index (RSI)
- ESSA 48.52
- VTYX 56.94
- Support Level
- ESSA $18.62
- VTYX $2.10
- Resistance Level
- ESSA $19.08
- VTYX $2.42
- Average True Range (ATR)
- ESSA 0.37
- VTYX 0.22
- MACD
- ESSA -0.01
- VTYX -0.02
- Stochastic Oscillator
- ESSA 43.52
- VTYX 53.99
About ESSA ESSA Bancorp Inc.
ESSA Bancorp Inc is a holding company, engaged in accepting deposits from the general public and investing those deposits, together with funds generated from operations and borrowings, in residential first mortgage loans (including construction mortgage loans), commercial real estate loans, home equity loans and lines of credit and commercial and industrial loans. The company offers a variety of deposit accounts, including checking, savings and certificates of deposit. The company also offers asset management and trust services and investment services. The company also offers insurance benefit consulting services through its wholly-owned subsidiary, ESSA Advisory Services, LLC.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.